Format

Send to

Choose Destination
BMC Cancer. 2017 Aug 24;17(1):567. doi: 10.1186/s12885-017-3552-6.

Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.

Li Y1,2, Chen QY1,2, Tang LQ1,2, Liu LT1,2, Guo SS1,2, Guo L1,2, Mo HY1,2, Chen MY1,2, Guo X1,2, Cao KJ1,2, Qian CN1,2, Zeng MS1, Bei JX1, Shao JY1,3, Sun Y1,4, Tan J1, Chen S1, Ma J1,4, Zhao C1,2, Mai HQ5,6.

Author information

1
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine,Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China.
2
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.
3
Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
4
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
5
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine,Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. maihq@sysucc.org.cn.
6
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China. maihq@sysucc.org.cn.

Abstract

BACKGROUND:

This study aimed to evaluate the long-term outcome and toxicities in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by concurrent chemoradiotherapy (CCRT) with/without adding cetuximab.

METHODS:

A total of 62 patients treated with CCRT plus cetuximab were matched with 124 patients treated with CCRT alone by age, sex, pathological type, T category, N category, disease stage, radiotherapy (RT) technique, Epstein-Barr virus (EBV) DNA levels, and Eastern Cooperative Oncology Group (ECOG). Overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed using the Kaplan-Meier method and log-rank test. Treatment toxicities were clarified and compared between two groups.

RESULTS:

A total of 186 well-balanced stage II to IV NPC patients were retrospectively analyzed (median follow-up, 76 months). Compared to CCRT alone, adding cetuximab resulted in more grade 3 to 4 radiation mucositis (51.6% vs. 23.4%; P < 0.001). No differences were found between the CCRT + cetuximab group and the CCRT group in 5-year OS (89.7% vs. 90.7%, P = 0.386), 3-year PFS (83.9% vs. 88.7%, P = 0.115), the 3-year LRFS (95.0% vs. 96.7%, P = 0.695), and the 3-year DMFS (88.4% vs 91.9%, P = 0.068). Advanced disease stage was the independent prognostic factor predicting poorer OS and PFS.

CONCLUSION:

Adding cetuximab to CCRT did not significantly improve benefits in survival in stage II to IV NPC and exacerbated acute mucositis and acneiform rash. Further investigations are warranted.

KEYWORDS:

Cetuximab; Cisplatin; Clinical outcome; Concurrent chemotherapy; Intensity-modulated radiotherapy; Nasopharyngeal carcinoma

PMID:
28836950
PMCID:
PMC5571586
DOI:
10.1186/s12885-017-3552-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center